Program
filgotinib
Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.
Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.
Drug pageGLPG0634: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lakefront Biotherapeutics NVits history only | 230 open or running | phase 3since Sep 22, 2016 | Aug 10, 2010 | none ahead |
| Gilead Sciencesits history only | 160 open or running | phase 3since Aug 17, 2016 | Aug 17, 2016 | none ahead |
| Alfasigma | 74 open or running | phase 3since Sep 22, 2016 | Sep 22, 2016 | Jun 2027phase 3 · NCT07554495 |
Also a collaborator on its studies: Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alfasigma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2016First study: phase 3 study in Colitis, UlcerativeFirst studyNCT02914535 · 1,173 enrolled · United States, Argentina, Australia and more
- Jan 17, 2017Phase 3 study in Arthritis, RheumatoidNCT03025308 · 2,731 enrolled · United States, Argentina, Australia and more
- Mar 14, 2023Phase 3 study in Axial SpondyloarthritisNCT05785611 · 495 enrolled · Belgium, Bulgaria, Czechia and more
- Jan 4, 2024Phase 1 study in Arthritis, JuvenileNCT06222034 · 9 enrolled · France, Germany, Poland and more
- Mar 4, 2025Phase 3 study in Colitis, UlcerativeNCT06865417 · 80 planned · Belgium, Croatia, France and more
- Apr 15, 20262 phase 3 studies in Arthritis, JuvenileNCT07554495, NCT07553182
Ahead
- Jun 2027Primary completion: phase 3 study in Arthritis, JuvenileNCT07554495
- Dec 2027Primary completion: phase 3 study in Arthritis, JuvenileNCT07553182
- Jun 2028Primary completion: phase 3 study in Colitis, UlcerativeNCT06865417
TargetBeta
“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 7 Alfasigma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07553182Arthritis, Juvenile · France, Germany, United Kingdom | 3 | Recruiting | Dec 2027 | 80 |
| NCT07554495Arthritis, Juvenile · Belgium, Czechia, France and more | 3 | Recruiting | Jun 2027 | 65 |
| NCT06865417Colitis, Ulcerative · Belgium, Croatia, France and more | 3 | Recruiting | Jun 2028 | 80 |
| NCT06222034Arthritis, Juvenile · France, Germany, Poland and more | 1 | Terminated | Jun 17, 2026 | 9 |
| NCT05785611Axial Spondyloarthritis · Belgium, Bulgaria, Czechia and more | 3 | Active, not recruiting | Sep 4, 2024 | 495 |
| NCT03025308Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | May 16, 2025 | 2,731 |
| NCT02914535Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Sep 8, 2026 | 1,173 |
How it is read
Names in the registry
- “Filgotinib”, 32 entries
- “GLPG0634”, 11 entries
- “filgotinib”, 3 entries
- “GLPG0634 50 mg”, 1 entry
- “GLPG0634 100 mg”, 1 entry
Codes read as this program: GLPG0634.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 12 studies
- Crohn Disease, 5 studies
- Colitis, Ulcerative, 4 studies
- Arthritis, Psoriatic, 4 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.